Solutions Ecosystems Reports Resources Data Pricing Login Book a demo
Power Law company profile

WuXi Biologics

Biotech & Life Sciences · Xuancheng, China · Founded 2000 · IPO 2017 Decacorn

WuXi Biologics - Discovery, Development, Manufacturing - CDMO - CMO. Spun out of WuXi AppTec

Valuation
$15B
Market cap · May/2026
Revenue
$3.00B
Latest reported FY
EBITDA
$1.34B
Latest reported FY

Investors

1 investor on WuXi Biologics's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series B+ 1 investor entered at this stage
Dinghang Capital

Global footprint

Where WuXi Biologics has talent and traffic

AI talent share
0.0% of workforce is AI talent
(1 of 2,990 staff)
Core AI00%
Other AI10.03%
Non-AI workforce2,98999.97%
Workforce by country
24 countries with
team presence
🇨🇳 China42.5%
🇮🇪 Ireland24.5%
🇺🇸 United States17.1%
🇩🇪 Germany8%
🇬🇧 United Kingdom4.1%
Top 5 of 24 shown
Web traffic by country
180K monthly visits
across markets
🇨🇳 China90.2%
🇺🇸 United States10.4%
🏳️ Korea1.8%
🏳️ Republic of1.6%
🇬🇧 United Kingdom1.1%
Top 5 markets shown

Patent intelligence

$112M patent portfolio · 318 active families

Estimated portfolio value
$112M
0.76% of market cap · 4.8× the top peer BillionToOne ($24M)
318 active patent families
Where WuXi Biologics innovates Molecular biologyAntiendomysial antibodiesExpression vectorBiochemistryImmunology

Where WuXi Biologics concentrates vs peers

Each axis is a top-10 topic across WuXi Biologics and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Capital deployed

WuXi Biologics's 10 investments and acquisitions.

Every disclosed deal where WuXi Biologics appeared as a backer or acquirer, 2020–2024. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

10 deals across WuXi Biologics's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        01 · Deployment strategy vs peers

        Where WuXi Biologics deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        02 · Portfolio market map

        WuXi Biologics's portfolio, mapped.

        Each chip is one company. Pill colour shows round type — green for Seed, blue for Series A, purple for B/C+, pink for late-stage, amber for M&A. Bigger sectors keep their full list behind “+ N more”.

        Stage
        Period
        10 of 10 deals

        Market sentiment

        What the market is saying about WuXi Biologics

        An AI-synthesized read of the highest-engagement posts about WuXi Biologics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See WuXi Biologics on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.